Microfluidics for Development of Lipid Nanoparticles: Paving the Way for Nucleic Acids to the Clinic

• Published in: ACS applied bio materials Vol. 6; no. 9; pp. 3566 - 3576
• Main Authors: Ali, Moustafa S., Hooshmand, Nasrin, El-Sayed, Mostafa, Labouta, Hagar I.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 18.09.2023
• Subjects: nanomedicine; nucleic acid therapies; microfluidics; mRNA, lipid nanoparticles
• ISSN: 2576-6422; 2576-6422
• DOI: 10.1021/acsabm.1c00732

Nucleic acid therapeutics hold an unprecedented promise toward treating many challenging diseases; however, their use is hampered by delivery issues. Microfluidics, dealing with fluids in the microscale dimensions, have provided a robust means to screening raw materials for development of nano delivery vectors, in addition to controlling their size and minimizing their polydispersity. In this mini-review, we are briefly highlighting the different types of nucleic acid therapies with emphasis on the delivery requirement for each type. We provide a thorough review of available methods for the development of nanoparticles, especially lipid nanoparticles (LNPs) that resulted in FDA approval of the first ever nucleic acid nanomedicine. We then focus on recent research attempts for how microfluidic synthesis of lipid nanoparticles and discuss the various parameters required for successful formulation of LPNs including chip design, flow regimes, and lipid composition. We then identify key areas of research in microfluidics and related fields that require attention for future success in clinical translation of nucleic acid nanomedicines.